• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.称重、测量，仍在探索：贝伐珠单抗在未经选择的晚期乳腺癌患者中的治疗作用。
Oncologist. 2011;16(12):1669-71. doi: 10.1634/theoncologist.2011-0403. Epub 2011 Dec 8.
2
Bevacizumab treatment for advanced breast cancer.贝伐珠单抗治疗晚期乳腺癌。
Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5.
3
Angiogenesis as a therapeutic target in breast cancer.血管生成作为乳腺癌的治疗靶点。
Mini Rev Med Chem. 2012 Oct;12(12):1230-8. doi: 10.2174/138955712802761988.
4
[Anti-angiogenic therapy in breast cancer].[乳腺癌的抗血管生成治疗]
Gan To Kagaku Ryoho. 2014 Feb;41(2):153-6.
5
Angiogenesis - still a worthwhile target for breast cancer therapy?血管生成——仍然是乳腺癌治疗的一个有价值的靶点吗？
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S19. doi: 10.1186/bcr2748.
6
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?克服HER2靶向药物在五线治疗中的耐药性：贝伐单抗在HER2阳性乳腺癌治疗中仍有一席之地吗？
Clin Breast Cancer. 2014 Feb;14(1):e17-20. doi: 10.1016/j.clbc.2013.09.009. Epub 2013 Sep 28.
7
Novel approaches to advanced breast cancer: bevacizumab and lapatinib.晚期乳腺癌的新治疗方法：贝伐单抗和拉帕替尼。
J Natl Compr Canc Netw. 2007 Mar;5(3):314-23. doi: 10.6004/jnccn.2007.0026.
8
Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it?转移性乳腺癌患者使用贝伐珠单抗治疗：它还有作用吗？
Curr Treat Options Oncol. 2012 Jun;13(2):249-62. doi: 10.1007/s11864-012-0181-9.
9
Benefit-risk assessment of bevacizumab in the treatment of breast cancer.贝伐珠单抗治疗乳腺癌的获益-风险评估。
Drug Saf. 2012 Jan 1;35(1):15-25. doi: 10.2165/11595910-000000000-00000.
10
Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot.贝伐单抗用于转移性乳腺癌的一线治疗：泽维尔·皮沃特的观点
Drugs. 2007;67(12):1800-1. doi: 10.2165/00003495-200767120-00011.

引用本文的文献

1
F-Alfatide II PET/CT for Identification of Breast Cancer: A Preliminary Clinical Study.F-Alfatide II PET/CT 用于乳腺癌识别：初步临床研究。
J Nucl Med. 2018 Dec;59(12):1809-1816. doi: 10.2967/jnumed.118.208637. Epub 2018 Apr 26.

本文引用的文献

1
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.贝伐珠单抗在转移性乳腺癌女性中的应用：一项关于临床实践和当前争议的调查。
Cancer. 2012 Jun 1;118(11):2780-6. doi: 10.1002/cncr.26579. Epub 2011 Oct 5.
2
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.贝伐珠单抗联合紫杉醇一线治疗转移性乳腺癌的成本效益分析。
Breast Cancer Res Treat. 2012 Apr;132(2):747-51. doi: 10.1007/s10549-011-1919-y. Epub 2011 Dec 27.
3
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?贝伐珠单抗治疗转移性乳腺癌：是敌是友？
Curr Oncol Rep. 2012 Feb;14(1):1-11. doi: 10.1007/s11912-011-0202-z.
4
Bevacizumab treatment for advanced breast cancer.贝伐珠单抗治疗晚期乳腺癌。
Oncologist. 2011;16(12):1684-97. doi: 10.1634/theoncologist.2011-0113. Epub 2011 Oct 5.
5
Bevacizumab for advanced breast cancer: all tied up with a RIBBON?贝伐单抗用于晚期乳腺癌：与RIBBON试验密切相关？
J Clin Oncol. 2011 Apr 1;29(10):1232-5. doi: 10.1200/JCO.2010.33.2684. Epub 2011 Mar 7.
6
Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.贝伐珠单抗治疗相关癌症患者的死亡率：一项荟萃分析。
JAMA. 2011 Feb 2;305(5):487-94. doi: 10.1001/jama.2011.51.
7
Progression-free survival remains debatable endpoint in cancer trials.无进展生存期在癌症试验中仍是一个有争议的终点指标。
J Natl Cancer Inst. 2009 Nov 4;101(21):1439-41. doi: 10.1093/jnci/djp399. Epub 2009 Oct 14.
8
Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.西妥昔单抗用于转移性结直肠癌的前瞻性成本效益分析：加拿大国立癌症研究所临床试验组CO.17试验评估
J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.
9
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.贝伐单抗联合紫杉醇治疗HER-2阴性转移性乳腺癌的经济学评估
Eur J Cancer. 2009 May;45(8):1397-406. doi: 10.1016/j.ejca.2008.12.016. Epub 2009 Jan 13.

称重、测量，仍在探索：贝伐珠单抗在未经选择的晚期乳腺癌患者中的治疗作用。

Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.

机构信息

Johns Hopkins Singapore International Medical Centre, Johns Hopkins University, Singapore, Republic of Singapore.

出版信息

Oncologist. 2011;16(12):1669-71. doi: 10.1634/theoncologist.2011-0403. Epub 2011 Dec 8.

DOI:10.1634/theoncologist.2011-0403
PMID:22156733
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3248764/
Abstract

The review of Alvarez et al. on the controversial role of bevacizumab in the treatment of advanced breast cancer, presented in this issue of , is examined.

摘要

本文对 Alvarez 等人在本期 杂志上发表的关于贝伐珠单抗在晚期乳腺癌治疗中存在争议的作用的综述进行了考察。